Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal
Completed
- Conditions
- Alcohol Dependence
- Registration Number
- NCT02146963
- Lead Sponsor
- Centre Hospitalier Esquirol
- Brief Summary
This study is complementary to the main study "Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal " NCT01491347.
The purpose of this study is to evaluate the Bdnf gene - Val66Met polymorphism in subjects with alcohol dependence according to their alcohol consumption status 6 months after withdrawal (relapse or abstinence), in relation to the presence of psychiatric co-morbidities.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
- participation to the study "BDNF serum levels evolution during 6 months after alcohol withdrawal" (main study)
- criteria from the main study
Exclusion Criteria
- criteria from the main study
- released or out from the main study before the follow-up at 4 months after withdrawal
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of the Bdnf gene Val/Val, Val/Met and Met/Met phenotypes as a function of relapse at the time of inclusion
- Secondary Outcome Measures
Name Time Method existence of a psychiatric co-morbidity at the inclusion (major depression, schizophrenia, anxiety disorder) at the time of inclusion serum BDNF levels variations between inclusion and 6 months later (or 4 months if the participants does not come for the 4 months-follow-up). 6 months after alcohol withdrawal presence of a psychiatric co-morbidity at 6 months after withdrawal (major depression, schizophrenia, anxiety disorder) 6 month after alcohol withdrawal
Trial Locations
- Locations (1)
Centre Hospitalier Esquirol
🇫🇷Limoges, France